Westover Capital Advisors Lifted Monsanto Co (MON) Position; Crestpoint Capital Management Has Boosted Its Bristol (BMY) Position

November 14, 2017 - By Michael Collier

Crestpoint Capital Management Llc increased Bristol (BMY) stake by 45.66% reported in 2017Q2 SEC filing. Crestpoint Capital Management Llc acquired 10,000 shares as Bristol (BMY)’s stock declined 1.04%. The Crestpoint Capital Management Llc holds 31,900 shares with $1.78M value, up from 21,900 last quarter. Bristol now has $100.35B valuation. The stock rose 0.54% or $0.33 reaching $61.31 per share. About 2.52 million shares traded. Bristol-Myers Squibb Co (NYSE:BMY) has declined 23.19% since November 14, 2016 and is downtrending. It has underperformed by 39.89% the S&P500.

Westover Capital Advisors Llc increased Monsanto Co (MON) stake by 43.27% reported in 2017Q2 SEC filing. Westover Capital Advisors Llc acquired 6,518 shares as Monsanto Co (MON)’s stock rose 6.51%. The Westover Capital Advisors Llc holds 21,582 shares with $2.55M value, up from 15,064 last quarter. Monsanto Co now has $51.98 billion valuation. The stock declined 0.06% or $0.07 reaching $118.08 on the news. About 901,472 shares traded. Monsanto Company (NYSE:MON) has risen 15.46% since November 14, 2016 and is uptrending. It has underperformed by 1.24% the S&P500.

Investors sentiment decreased to 0.95 in 2017 Q2. Its down 0.03, from 0.98 in 2017Q1. It turned negative, as 78 investors sold BMY shares while 520 reduced holdings. 120 funds opened positions while 451 raised stakes. 1.10 billion shares or 2.26% less from 1.12 billion shares in 2017Q1 were reported. Vantage Ltd Liability Corp holds 0.09% or 5,843 shares. 166,260 are held by Synovus. Orrstown Fincl Services has 600 shares. High Pointe Capital Management Lc holds 26,700 shares. Piedmont Inv Advisors Limited Liability Corp has invested 0.54% in Bristol-Myers Squibb Co (NYSE:BMY). Arete Wealth Advisors Ltd Liability Company invested in 0.22% or 8,782 shares. Peapack Gladstone Fin Corp invested 0% in Bristol-Myers Squibb Co (NYSE:BMY). Ecor1 Capital Limited Com has 17,060 shares for 0.17% of their portfolio. Comml Bank Hapoalim Bm invested in 0.02% or 1,800 shares. Moreover, Reynders Mcveigh Cap Mgmt Limited has 0.21% invested in Bristol-Myers Squibb Co (NYSE:BMY) for 28,466 shares. Provise Mgmt Gp Ltd Co holds 0.13% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY) for 15,756 shares. Veritable Lp invested in 0.33% or 262,898 shares. Moreover, Round Table Ltd Liability has 0.08% invested in Bristol-Myers Squibb Co (NYSE:BMY) for 4,018 shares. Train Babcock Advisors Ltd Com has 5,077 shares. The Massachusetts-based Wilkins Counsel Inc has invested 0.07% in Bristol-Myers Squibb Co (NYSE:BMY).

Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 3 Sell and 10 Hold. Therefore 32% are positive. Bristol-Myers Squibb Company had 67 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co with “Hold” on Monday, August 14. The firm has “Buy” rating by Leerink Swann given on Thursday, July 27. The firm has “Buy” rating by Citigroup given on Tuesday, September 20. The stock of Bristol-Myers Squibb Co (NYSE:BMY) earned “Outperform” rating by Leerink Swann on Monday, October 23. The rating was maintained by Jefferies on Tuesday, March 15 with “Hold”. The firm has “Equal-Weight” rating by Barclays Capital given on Friday, October 13. As per Friday, September 9, the company rating was maintained by Barclays Capital. Piper Jaffray maintained it with “Hold” rating and $60.0 target in Friday, September 22 report. The firm has “Buy” rating given on Friday, April 29 by UBS. The rating was maintained by UBS on Friday, October 6 with “Buy”.

Crestpoint Capital Management Llc decreased Pfizer (NYSE:PFE) stake by 38,700 shares to 22,900 valued at $769,000 in 2017Q2. It also reduced Tribune Media stake by 26,800 shares and now owns 8,300 shares. Kroger (NYSE:KR) was reduced too.

Among 23 analysts covering Monsanto Company (NYSE:MON), 12 have Buy rating, 0 Sell and 11 Hold. Therefore 52% are positive. Monsanto Company had 59 analyst reports since August 25, 2015 according to SRatingsIntel. On Thursday, October 8 the stock rating was reinitiated by JP Morgan with “Neutral”. The rating was maintained by RBC Capital Markets on Tuesday, September 5 with “Hold”. The rating was maintained by Jefferies on Monday, August 14 with “Hold”. On Friday, November 18 the stock rating was upgraded by OTR Global to “Mixed”. The rating was upgraded by CLSA on Friday, January 6 to “Outperform”. The rating was maintained by Barclays Capital on Thursday, October 5 with “Equal-Weight”. The firm has “Buy” rating by Canaccord Genuity given on Tuesday, August 25. The company was downgraded on Friday, August 18 by UBS. The firm earned “Buy” rating on Thursday, October 8 by Deutsche Bank. The rating was maintained by UBS with “Buy” on Tuesday, June 14.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com